Download PDF
Dtsch Med Wochenschr 2014; 139(06): 261-263
DOI: 10.1055/s-0033-1360018
Nephrologie | Commentary
Nephrologie
© Georg Thieme Verlag KG Stuttgart · New York

Chronisches Nierenversagen – Update 2014

Chronic kidney disease – update 2014
C. Wanner
1   Medizinische Klinik und Poliklinik 1, Schwerpunkt Nephrologie, Universitätsklinikum Würzburg
,
M. Ketteler
2   Nephrologische Abteilung, Medizinische Klink III, Klinikum Coburg
› Author Affiliations
Further Information

Publication History

Publication Date:
28 January 2014 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

chronische Nierenkrankheit - Prinzipien der Progressionshemmung - Phosphatbinder und Überleben - Calcium- und Phosphatbilanz bei CKD - KDIGO-Lipidrichtlinien

Keywords

chronic kidney disease (CKD) - principles of inhibiting progression - phosphate binders and survival - calcium and phosphate balance in CKD - KDIGO lipid guidelines
 

  • Literatur

  • 1 Block GA, Wheeler DC, Persky MS et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012; 23: 1407-1415
    CrossrefPubMedGoogle Scholar
  • 2 Cannata-Andía JB, Fernández-Martín JL, Locatelli F et al. Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int 2013; 84: 998-1008
    CrossrefPubMedGoogle Scholar
  • 3 de Zeeuw D, Akizawa T, Audhya P et al. the BEACON Trial Investigators. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013; 2013; 369: 2492-2503
    CrossrefPubMedGoogle Scholar
  • 4 Fried LF, Emanuele N, Zhang JH et al. VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369: 1892-1903
    CrossrefPubMedGoogle Scholar
  • 5 Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
    CrossrefPubMedGoogle Scholar
  • 6 Hill KM, Martin BR, Wastney ME et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int 2013; 83: 959-966
    CrossrefPubMedGoogle Scholar
  • 7 Isakova T, Wolf MS. FGF23 or PTH: which comes first in CKD?. Kidney Int 2010; 78: 947-949
    CrossrefPubMedGoogle Scholar
  • 8 Iseki K, Ikemiya Y, Iseki C et al. Proteinuria and the risk of developing end-stage renal disease. Kidney Int 2003; 63: 1468-1474
    CrossrefPubMedGoogle Scholar
  • 9 Jamal SA, Vandermeer B, Raggi P et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 2013; 382: 1268-1277
    CrossrefPubMedGoogle Scholar
  • 10 Ketteler M, Wanner C. Chronisches Nierenversagen – Update 2012. Dtsch Med Wochenschr 2012; 137: 2023-2025
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Mann JF, Gerstein HC, Pogue J et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629-636
    CrossrefPubMedGoogle Scholar
  • 12 Mann JF, Schmieder RE, McQueen M et al. ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study). Lancet 2008; 372: 547-553
    CrossrefPubMedGoogle Scholar
  • 13 Parving HH, Brenner BM, McMurray JJ et al. ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204-2213
    CrossrefPubMedGoogle Scholar
  • 14 Pergola PE, Raskin P, Toto RD et al. BEAM Study Investigators. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011; 365: 327-336
    CrossrefPubMedGoogle Scholar
  • 15 Shlipak MG, Matsushita K, Ärnlöv J et al. CKD Prognosis Consortium. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med 2013; 369: 932-943
    CrossrefPubMedGoogle Scholar
  • 16 Stone NJ, Robinson J, Lichtenstein AH et al. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; pii: S0735-1097(13)06028-2
    PubMedGoogle Scholar
  • 17 Susantitaphong P, Sewaralthahab K, Balk EM et al. Short- and long-term effects of alkali therapy in chronic kidney disease. Am J Nephrol 2012; 35: 540-547
    CrossrefPubMedGoogle Scholar
  • 18 Tonelli M, Wanner C. for the Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2013 Clinical Practice Guideline. Ann Intern Med 2013; doi: DOI: 10.7326/M13-2453.
    PubMedGoogle Scholar
  • 19 Tonelli M. The roads less traveled? Diverging research and clinical priorities for dialysis patients and those with less severe CKD. Am J Kidney Dis 2014; 63: 124-132
    CrossrefPubMedGoogle Scholar
  • 20 van der Velde M, Matsushita K, Coresh J et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011; 79: 1341-1352
    CrossrefPubMedGoogle Scholar